Fig. 3
Effect of candidate drugs on ISR markers in vehicle control (blue circle) or 0.1 μM MG132-treated (orange triangle) VWMD1 EIF2B5R113H/A403V patient iPSC-derived astrocytes. Cells were treated with candidate drugs, with or without MG132 for 24 h. Protein expression was measured by western blot and normalised to total protein for the ISR markers: a phosphorylated eIF2α, normalised to eIF2α; b GADD34; c CHOP. Individual data points are shown with mean ± SEM (n = 4). Significant differences were identified by two-way ANOVA, followed by Holm-Sidak posthoc test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Representative western blots shown in (Figure S3)